

Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation

TETSUYA BEPPU¹, KAZUSHI SUGIMOTO¹, KATSUYA SHIRAKI¹, MASAHICO TAMEDA¹, SATOKO KUSAGAWA¹, KEIICHIRO NOJIRI¹, JUNICHIRO TANAKA¹, NORIHIKO YAMAMOTO¹, YOSHIYUKI TAKEI¹, HARUYUKI TAKAKI², JUNJI URAKI², ATSUHIRO NAKATSUKA², KOICHIRO YAMAKADO² and KAN TAKEDA²

Departments of ¹Gastroenterology and ²Radiology, Mie University School of Medicine, Tsu, Mie 514-8507, Japan

Received March 19, 2010; Accepted May 10, 2010

DOI: 10.3892/ijmm_00000482

Abstract. The aim of this study was to elucidate the importance of three tumor markers, α -fetoprotein (AFP), *Lens culinaris* agglutinin A-reactive fraction of AFP (AFP-L3), and des- γ -carboxy prothrombin (DCP), for detecting and predicting the recurrence of hepatocellular carcinomas (HCCs). A total of 108 patients with initial non-advanced HCC who underwent curative radiofrequency ablation (RFA) in our hospital were enrolled in this study. The effectiveness of the three tumor markers for detecting recurrence and recurrence-free survival was analyzed. Positivity of these three makers was not markedly increased at the first or second recurrence. In addition, there was no significant correlation between the initial and recurrent levels of each tumor marker. The tumor marker that was positive at the time of initial HCC was not necessarily positive at recurrence. The tumor marker levels at recurrence were not correlated with pre-ablation levels. No significant correlation was found in the tumor marker values between pre-ablation and the time of recurrence. On multivariate analysis, high AFP-L3 levels ($\geq 10\%$) were significantly predictive of recurrence-free survival. All three tumor markers should be routinely measured to detect recurrence during follow-up after RFA. Especially high AFP-L3 levels should be followed closely.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and its incidence is still increasing in various regions (1-3). Current options for the treatment of

HCC consist of surgical resection, orthotopic liver transplantation, transcatheter arterial embolization (TACE) and percutaneous ablation therapy. Surgical resection has been considered to be the best treatment for early-stage HCCs, but only 9-29% of patients with HCC are candidates for surgery, owing to either underlying chronic liver disease resulting in poor hepatic reserve or a multifocal distribution of tumor nodules (4). Radiofrequency ablation (RFA) was first described by Rossi *et al* (5) and it is a relatively new technique for local HCC therapy, with many studies having demonstrated its clinical utility and safety (6-8). A high local cure rate can be achieved without adversely affecting background liver function, and it has been playing an important role in the treatment of HCC (9).

We have shown that RFA combined with chemoembolization provides overall and recurrence-free survival rates comparable to those achieved with hepatectomy in patients with early-stage HCC (4). The local tumor progression rate following RFA combined with chemoembolization (combination therapy) was lower than the rates in previous studies that used RFA alone (10-12). Despite good control of treated lesions, new tumors frequently occur, resulting in high distant recurrence rates (4,6).

Therefore, it is very important to detect recurrence of HCCs early. For this purpose, serum tumor markers have been used for a long time because of their convenience, inexpensiveness, and their satisfactory accuracy, and they could be valuable supplementary investigations to ultrasonography and computer tomography (CT) for the diagnosis of HCC. Using an appropriate single tumor marker or combination of tumor markers may improve the effectiveness of screening HCC patients (13).

Several tumor markers for HCC have been reported (14-20). Three tumor markers specific to HCC are currently used in Japan, AFP, AFP-L3 and DCP, which is also referred to as protein induced by vitamin K absence II (PIVKA II) (21).

Previous reports have detailed the usefulness of each of these tumor markers in the early detection and diagnosis of HCC, the evaluation of tumor progression, and the determination of patient prognosis (21-26), although these tumor markers do not demonstrate high positivity in patients with small (e.g., less than 2 cm in maximum diameter) HCC (27,28). Of these, AFP shows relatively low specificity (29),

Correspondence to: Dr Katsuya Shiraki, Department of Gastroenterology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan
E-mail: katsuyas@clin.medic.mie-u.ac.jp

Key words: hepatocellular carcinoma, radiofrequency ablation, α -fetoprotein, *Lens culinaris* agglutinin A-reactive fraction of AFP, des- γ -carboxy prothrombin

Table I. Baseline characteristics of the patients.

Variable	All patients (n=108) (%)
Age (years)	67.3±8.4
Gender (male/female)	77 (71)/31 (29)
HBsAg positive	10 (9)
HCVAb positive	89 (82)
AST (IU/ml) ^a	52.5 (19-157)
ALT (IU/ml) ^a	45.5 (13-162)
Child-Pugh class (A/B)	83 (77)/25 (23)
Albumin (g/dl) ^a	3.5 (2.2-4.7)
Total bilirubin (mg/dl) ^a	0.8 (0.3-1.9)
Prothrombin time (%) ^a	84.7 (56.4-117)
Platelets (x10 ⁴ /mm ³) ^a	9.9 (3.2-34.1)
Maximum tumor size (cm) ^a	2.4 (1-5)
<3	85 (79)
≥3	23 (21)
No. of tumors ^a	1 (1-4)
Uninodular	72 (67)
Multinodular	36 (33)

^aData are expressed as median (range). HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

because AFP increases in association with hepatocyte regeneration and is also associated with serum alanine aminotransferase activity (9). These studies recommend the simultaneous measurement of these tumor markers in the follow-up of patients with chronic liver diseases. However, only a few studies have examined the significance of tumor markers in the prediction, detection and diagnosis of HCC recurrence after local curative treatment using RFA. Therefore, we investigated the use of these three tumor markers in the detection of recurrent HCCs after curative ablation.

Patients and methods

Patients. Subjects included 108 patients with initial HCC who underwent RFA after TACE for treatment of HCC between April 2000 and April 2008 at Mie University Hospital. Inclusion criteria were: i) no previous treatment for HCC; ii) a single HCC of ≤5 cm in diameter or up to three HCCs, each of which was ≤3 cm in diameter; iii) liver cirrhosis classified as Child-Pugh class A and B; iv) no vascular invasion; and v) no extrahepatic metastases. Patient background data are summarized in Table I. Of the 108 patients, 77 (71%) were men and 31 (29%) were women, with a mean age of 67.3 years. In all, 89 patients (82%) were

positive for anti-HCV antibody and 10 (9%) patients were positive for HBs antigen. With regard to Child-Pugh classification, 83 (77%) patients were class A and 25 (23%) were class B. The median (range) levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (Alb), total bilirubin (T-Bil), prothrombin time (PT) and platelet counts (Plt) were 52.5 IU/l (19-157), 45.5 IU/l (13-162), 3.5 g/dl (2.2-4.7), 0.8 mg/dl (0.3-1.9), 84.7% (56.4-117) and 9.9x10⁴/mm³ (3.2-34.1), respectively.

Diagnosis of HCC was primarily established based on radiological findings and elevated tumor marker values. If a hepatic nodular lesion was found on screening ultrasonography, the patient underwent dynamic CT and/or dynamic magnetic resonance imaging (MRI) for further evaluation. Furthermore, in cases with a liver nodule that showed hyperattenuation in the arterial phase of the dynamic study and washout in the portal or delayed phase or typical hypervascular staining on digital subtraction angiography, the nodule was diagnosed as HCC. When the nodule did not show the above-mentioned typical imaging features, a fine-needle aspiration biopsy was carried out for histological examination and diagnosis.

In this study, 72 (67%) patients had a single HCC nodule and 36 (33%) had multiple nodules. The median (range) maximum tumor diameter was 2.4 cm (1-5); 23 (21%) patients had tumors of ≥3 cm and 85 (79%) patients had tumors <3 cm (Table I). The median (range) follow-up period was 32.3 (6.1-76) months.

Chemoembolization. All patients underwent chemoembolization prior to RFA. After celiac, superior mesenteric and hepatic arteriography, a 3F micro-catheter (Micro Pheret, William Cook Europe, Bjaevskov, Denmark) was advanced into the arteries supplying each tumor. The feeding arteries were embolized with gelatin sponge particles (Spongel, Yamanouchi, Tokyo, Japan) after a mixture of 2-8 ml iodized oil (Lipiodol Ultra-Fluid, Mitsui, Tokyo, Japan) and 40 mg of epirubicin hydrochloride (Farmorubicin, Kyowa Hakko, Tokyo, Japan) was injected into the arteries.

Radiofrequency ablation. Because the gelatin sponge remains in the tumor for 2-3 weeks after chemoembolization, RFA was generally performed within 2 weeks after TACE. RFA was performed using a 17-gauge, straight electrode with a 2- or 3-cm exposed tip (Cool-tip single needle, Radionics, Burlington, MA, USA) connected to an RF generator (Cool-tip RF generator, Radionics).

If the ablation was thought to be incomplete, the second ablation session was performed the next week to complete therapy. The end-point of RFA was the presence of a well-defined area of non-enhancing tissue, consisting of the treated tumor with a tumor-free margin of at least 5 mm in the arterial and portal phases on enhanced CT imaging. Patients received additional sessions of ablation until complete ablation was confirmed in each nodule.

Therapeutic effects and diagnosis of recurrence. Contrast-enhanced CT was performed to evaluate local therapeutic effects 1 week after RFA to check the efficacy of therapy. Subsequently, contrast-enhanced CT was performed every



to detect recurrence early. If a hepatic tumor was but did not present the typical enhancement pattern on CT, superparamagnetic iron oxide-enhanced magnetic resonance imaging was performed. In this study, 8 cases received anti-viral therapy with interferon after RFA, and HCV disappeared in three patients. Also, 600 mg of urso-deoxycholic acid were given to most patients. Distant recurrence was defined as the appearance of new tumors at an intrahepatic site distant from the treated tumors. When recurrence was suspected, angiography together with CTAP and CTHA was performed to make a definitive diagnosis.

Measurement of tumor markers. AFP, AFP-L3 and DCP levels were measured in serum samples obtained from each patient at the time of HCC diagnosis. The serum AFP levels were determined by enzyme-linked immunosorbent assay using a commercially available kit (ELISA-AFP, International Reagents, Kobe, Japan). Serum AFP-L3 levels were measured by lectin-affinity electrophoresis coupled with antibody-affinity blotting (AFP Differentiation kit L, Wako Pure Chemical Industries, Ltd., Osaka, Japan) and expressed as a percentage of the total AFP (AFP-L3 level/total AFP X 100). The serum DCP levels were determined by sensitive enzyme immunoassay (Eitest PIVKA II kit, Eisai Laboratory, Tokyo, Japan) according to the manufacturer's instructions. The cut-off levels for each tumor marker were 100 ng/dl for AFP, 10% for AFP-L3 and 40 mAU/ml for DCP, based on previous reports. AFP-L3 in patients with AFP values <10 ng/dl was determined as 0%, because AFP-L3 is normally quantifiable only in patients with AFP values above 10 ng/dl.

Statistical analysis. Survival and recurrence-free survival rates were computed using Kaplan-Meier estimates, and the Kaplan-Meier method and log-rank test were used to analyze predictive factors for recurrence-free survival of HCC. To identify independent factors associated with the recurrence-free survival rates, various likely predictors associated with recurrence-free survival on univariate analysis were subjected to multivariate analysis.

The Cox proportional hazards model was used for multivariate analysis. The factors included for analyses were patient aspartate aminotransferase (AST ≥ 52 IU/l/<52 IU/l), alanine aminotransferase (ALT ≥ 45 IU/l/<45 IU/l), serum albumin (Alb ≤ 3.5 g/dl/>3.5 g/dl), prothrombin time (PT <84%/≥84%), platelet counts (Plt $<10 \times 10^4/\geq 10 \times 10^4/\text{mm}^3$), pretreatment AFP-L3 level (<10%/≥10%) and pretreatment DCP level (<40 mAU/ml/≥40 mAU/ml). A P-value <0.05 was considered statistically significant. Analyses were performed using the StatView statistics package (SAS Institute, Cary, NC, USA).

Results

Overall recurrence-free survival rate and recurrence rate after initial RFA. The recurrence-free survival rates were 86.2 and 23.2% at 1 and 5 years, respectively. Of the 108 patients, 2 had local recurrences during the follow-up period. Locally recurrent tumors were treated by TACE followed by RFA. The overall local recurrence rate was 3.5%, and the overall distant recurrence rate was 66.3% at 5 years (data not shown).

Table II. Tumor marker levels.

Variable	N (%)
AFP (ng/dl)	26 (2-3173)
<100	87 (81)
≥100	21 (19)
AFP-L3 (%)	2.8 (0-89)
<10	83 (77)
≥10	25 (23)
DCP (mAU/ml)	27 (1.5-25750)
<40	64 (59)
≥40	44 (41)
AFP, ALP-L3, DCP	
<100 ng/dl, <10% and <40 mAU/ml	47 (44)
≥100 ng/dl or ≥10% or ≥40 mAU/ml	61 (56)

AFP, α -fetoprotein; AFP-L3, *Lens culinaris* is agglutinin A-reactive fraction of α -fetoprotein; DCP, des- γ -carboxy prothrombin.

Pre-treatment positivity for each tumor marker. We defined AFP equal to or >100 ng/ml, AFP-L3 equal to or >10% and DCP ≥ 40 mAU/ml as positive. Table II shows the rate of AFP, AFP-L3 and DCP positivity: 21 (19%) patients were positive for AFP, 25 (23%) patients were positive for AFP-L3 and 44 (41%) patients were positive for DCP before initial HCC treatment, while 47 (44%) patients were positive for none of these three markers.

Positive tumor marker rates at HCC recurrence. To verify the importance of three tumor markers for the diagnosis of recurrence, the positivity rates for each tumor marker at the initial diagnosis, first recurrence, and second recurrence were established. AFP was positive in 19%, 14% of patients at the initial diagnosis and first recurrence, then increased to 33% of patients at the second recurrence. AFP-L3 was positive in 23% at initial diagnosis, then increased to 33% at first recurrence, but decreased to 20% at second recurrence. DCP was positive in 41%, 47% at the initial diagnosis and first recurrence, then decreased to 27% of patients at the second recurrence (Fig. 1). The number of positive tumor markers did not increase with repeated recurrence (Fig. 2).

Tumor markers pre-ablation and at recurrence. We plotted the values of each tumor marker immediately before ablation and at recurrence. For each tumor marker, no correlation was found between the pre-ablation value and the value at the time of recurrence (AFP, $R=0.079$ $P=0.461$; AFP-L3, $R=0.064$ $P=0.704$; DCP, $R=0.015$ $P=0.893$) (Fig. 3).

Interestingly, in the patients who were positive for AFP, AFP-L3 and DCP at the initial HCC, 82, 44 and 42% were negative for the corresponding marker at the time of recurrence, respectively. Furthermore, in the patients who were negative for AFP, AFP-L3 and DCP at the initial HCC, 18, 26 and 29%, respectively, were positive for the corresponding marker when recurrence was diagnosed (data not shown).




Figure 1. Positivity rates (%) for each tumor marker [(A) AFP (100 ng/ml), (B) AFP-L3 (10%), (C) DCP (40 mAU/ml)] at the initial diagnosis, first recurrence and second recurrence. AFP, α -fetoprotein; AFP-L3, *Lens culinaris* agglutinin A-reactive fraction of α -fetoprotein; DCP, des- γ -carboxy prothrombin.




Figure 2. The number (0-3) of positive tumor markers at the initial diagnosis, first, second and third recurrence.

Recurrence-free survival rate after RFA by tumor marker. In the patients with AFP (100 ng/dl, recurrence-free survival rates were 66.6 and 22.2% at 2 and 4 years, respectively, whereas in the patients with AFP <100 ng/dl, recurrence-free survival rates were 60.8 and 24.4% at 2 and 4 years, respectively (NS) (Fig. 4A). In the AFP-L3 (10% patients, recurrence-free survival rates were 41.9 and 11.2% at 2 and 4 years, respectively, whereas in the AFP <10% patients, recurrence-free survival rates were 67.8 and 26.5% at 2 and 4 years, respectively ($P < 0.05$) (Fig. 4B). In the DCP (40 mAU/dl

patients, recurrence-free survival rates were 44.6 and 20.6% at 2 and 4 years, respectively, whereas in the DCP <40 mAU/dl patients, recurrence-free survival rates were 72.0 and 23.3% at 2 and 4 years, respectively (NS) (Fig. 4C).

Predictive factors for cumulative recurrence-free survival. Table III shows the predictive factors for cumulative recurrence-free survival according to the Kaplan-Meier method in all patients. Significantly lower recurrence-free survival rates were seen in cases with low Alb levels and high AFP-L3 levels




Figure 3. Scatter plots of (A) α -fetoprotein, (B) *Lens culinaris* agglutinin-reactive fraction AFP, (C) des- γ -carboxy prothrombin pre-ablation and at recurrence. AFP, α -fetoprotein; AFP-L3, *Lens culinaris* agglutinin A-reactive fraction of α -fetoprotein; DCP, des- γ -carboxy prothrombin.

on univariate analysis. Table IV shows the predictive factors for cumulative recurrence-free survival after RFA according to Cox proportional hazards regression; low Alb (Alb ≤ 3.5 g/dl) levels (HR=2.821, 95% CI 1.359-5.857 $P=0.0054$) and high AFP-L3 (AFP-L3 $\geq 10\%$) levels (HR=2.138, 95% CI 1.087-4.207 $P=0.0277$) were the risk factors. High AFP-L3 levels (AFP-L3 $\geq 10\%$) had significantly lower recurrence-free survival rate than low levels on multivariate analysis ($P=0.0277$), whereas the other two markers levels did not show association.

Discussion

The local progression rate following RFA alone has been previously reported to be as high as 17-35% over a mean follow-up period of 16-25.7 months (10-12). The local recurrence rate after RFA in this study was considerably lower (3.5% at 5 years) compared to previous reports, even though 23 (21%) of patients had HCCs larger than 30 mm in diameter. Real-time CT guidance is very useful for ensuring precise positioning of electrode insertion into the HCC nodules even if the lesion is located in the subcapsular or subphrenic region, and it is thus useful for obtaining sufficient ablation margins (30). Despite good control of treated lesions, new tumors frequently occur in the different regions of the liver. Previous studies have reported intra-hepatic distant recurrence rates of 18.7-22.5%, 62.1-67% and 81-81.7% at 1, 3 and 5 years, respectively, after percutaneous ethanol injection therapy (PEIT) (31-33), 38 and 60% at 1 and 2

years, respectively, after RFA (34), and 18 and 52% at 1 and 2 years, respectively, after RFA or microwave coagulation therapy (35). In the present subjects, distant recurrence occurred in 8.3, 19.3 and 66.3% at 1, 3 and 5 years, respectively, after the combination of TACE and RFA; these rates were comparable to those reported previously (31-35). The recurrences of HCC decrease liver function and worsen prognosis. Therefore, it is important to detect and treat HCC recurrence in the early stage to improve prognosis.

Three tumor markers (AFP, AFP-L3, DCP) have been used in the diagnosis of HCCs (14-20). The measurement of the levels of these three tumor markers provides additional important information for the management of patients with HCC. However, positivity rates of these three tumor markers for small HCCs less than 20 mm in diameter are as low as 20-40% and are thus unsatisfactory (27). Over 30% of patients with small HCC are positive for none of these three markers (27).

On the other hand, there are few reports concerning the significance and clinical utility of these tumor markers for determining the risk of and detecting recurrent HCCs.

At first, we determined the cut-off levels for the three tumor markers. AFP is currently the most widely used marker for diagnosing and monitoring the development of HCC (15,22,36). It has a sensitivity of 39-65%, a specificity of 76-94% and a positive predictive value of 9-50% (29). The higher the AFP cut-off level, the higher the specificity and the lower the sensitivity (37-39). We set the cut-off level of AFP as 100 ng/ml, based on a review of several papers




Figure 4. Cumulative recurrence-free survival rates by elevation of pre-treatment (A) α -fetoprotein (AFP) in patients who underwent the combination of chemoembolization and RFA. There is no significant difference between patients with or without elevated pretreatment AFP levels (P=0.7045). Cumulative recurrence-free survival rates by elevation of pretreatment (B) *Lens culinaris* agglutinin A-reactive fraction of AFP (AFP-L3) in patients who underwent the combination of chemoembolization and RFA. The recurrence-free survival rate is significantly lower in patients with than without elevated pretreatment AFP-L3 levels (P=0.0231). Cumulative recurrence-free survival rates by elevation of pretreatment (C) des- γ -carboxy prothrombin (DCP) in patients who underwent the combination of chemoembolization and RFA. There is no significant difference between patients with and without elevated pretreatment DCP levels (P=0.0512).

(9,15,28,29) that reported that this level is suitable for detecting HCCs. In order to improve the specificity of AFP in the diagnosis of HCC, AFP-L3 has been developed. AFP-L3 levels had sensitivities and specificities that ranged from 36-96% and 89-94%, respectively, though for the diagnosis of small HCCs, the specificity is relatively low, around 20% (20,28). Pre-treatment AFP-L3 values have also been reported to be correlated with poorly differentiated cancer and poor prognosis (40,41). Another common tumor marker for HCC is PIVKA II, also known as DCP, which results from an acquired defect in the post-translational carboxylation of the prothrombin precursor in HCC cells. Using DCP levels, sensitivities for detecting HCC ranged from 23-57%. Overall, AFP and DCP have nearly equal sensitivity, although DCP has higher specificity (23-26). We set the cut-off level of AFP-L3 and DCP as 10% and 40 mAU/ml, respectively, based on previous reports (20,23-26,28,40,41).

In our subjects, the pretreatment AFP, AFP-L3 and DCP values were positive in 19, 23 and 41% of patients, respectively. The positivity rates of AFP and AFP-L3 seemed to

be low, because 35% of HCCs are smaller than 20 mm in diameter. Forty-seven (44%) patients showed no elevations of any tumor markers, indicating that many RFA-treatable patients showed no tumor marker positivity. These results indicate the limitations of using tumor markers for detecting HCC.

Next, we analyzed these three tumor markers for detecting recurrent HCCs. The rate of AFP, AFP-L3 and DCP positivity did not increase in either the first or the second recurrence of HCCs. Previously it was reported that the AFP-L3-positive rate increased with recurrence. This may suggest that the diagnostic value of AFP-L3 increases during the clinical course of HCC (41). However, the positivity rates for the three makers did not increase significantly with the first or the second recurrence.

The changes of each tumor marker and tumor marker positivity in each patient were examined according to recurrence stages. Surprisingly, no correlation was found for any of the markers between the pre-ablation values and the values at recurrence. Patients who were positive for AFP, AFP-L3 and DCP at the initial HCC did not always have up-regulation of the tumor markers at recurrence. Inversely, patients who



SPANDIDOS PUBLICATIONS. Predictive factors for recurrence-free survival (multivariate analysis).

Variable	Cumulative probability of recurrence-free survival (%)		P-value
	2 years	4 years	
Age			
<67	63.8	22.6	0.8863
≥67	60.3	23.0	
Gender			
Male	60.5	23.2	0.9676
Female	66.1	23.4	
Size of tumor			
<25 mm	85.6	20.4	0.9091
≥25 mm	64.9	23.9	
AST			
<52 IU/l	69.2	27.3	0.113
≥52 IU/l	54.9	19.3	
ALT			
<45 IU/l	65.5	25.1	0.4606
≥45 IU/l	58.2	22.7	
Alb			
>3.5 g/dl	76.1	34.7	0.0039
≥3.5 g/dl	49.6	13.1	
T-Bil			
<0.8 mg/dl	62.2	22	0.6158
≥0.8 mg/dl	61.6	25.4	
PT			
≥84%	68.1	30.5	0.1021
<84%	55.6	15.9	
Plt			
≥10x10 ⁴ /mm ³	64	35.2	0.2086
<10x10 ⁴ /mm ³	59.7	14.6	
AFP pre-ablation			
<100 ng/ml	60.8	24.4	0.7045
≥10 ng/ml	66.6	22.2	
AFP-L3 pre-ablation			
<10%	67.8	26.5	0.0231
≥10%	41.9	11.2	
DCP pre-ablation			
<40 mAU/ml	72	23.3	0.0512
≥40 mAU/ml	44.6	20.6	

Alb, albumin; AFP-L3, *Lens culinaris* is agglutinin A-reactive fraction of α -fetoprotein; AFP, α -fetoprotein; DCP, des- γ -carboxy prothrombin; T-Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; Plt, platelet counts.

Table IV. Predictive factors for recurrence-free survival (multivariate analysis).

Factors	Relative risk	95% CI	P-value
Alb ≤3.5 g/dl	2.821	1.359-5.857	0.0054
AFP-L3 ≥10%	2.138	1.087-4.207	0.0277
DCP ≥40 mAU/ml	1.751	0.965-3.174	0.0653
AST >52 IU/l	1.991	0.857-4.628	0.1093
Plt <10x10 ⁴ /mm ³	1.122	0.542-2.323	0.7588
PT <84%	1.117	0.529-2.361	0.7711
ALT >45 IU/ml	0.921	0.377-2.242	0.8542

Alb, albumin; AFP-L3, *Lens culinaris* is agglutinin A-reactive fraction of α -fetoprotein; DCP, des- γ -carboxy prothrombin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; Plt, platelet counts.

were negative for AFP, AFP-L3 and DCP at the initial HCC did not always have tumor marker values in the normal range at recurrence. Presumably, these facts are due to changes in the properties and degree of differentiation of HCC cells, because HCC cells are very heterogeneous; multicentric occurrence is another possibility that may cause these discrepancies. Based on these results, these three tumor markers appear to be independently increased and all need to be measured to screen for HCC recurrence after RFA. The measurement of the levels of the three tumor markers provides additional important information.

Since local control is excellent, multicentric recurrence was more dominant in more than half of the cases of intrahepatic recurrence in our subjects (42). Kumada *et al* (43) determined that 50.9% of recurrent tumors were multicentric in origin, and that 49.1% were intrahepatic metastases. Sugimoto *et al* (44) estimated that about 45% of recurrent tumors were of multicentric origin, with the others being intrahepatic metastases, based on either imaging findings or the above morphologic criteria. The present results suggest that multicentric recurrence is more prevalent after RFA.

Next, we examined the significance of tumor markers in recurrence-free survival and prediction of HCCs. Our study demonstrated that the cumulative recurrence-free rates after 2 and 4 years were independent of AFP and DCP positivity. However, the cumulative recurrence-free rates were significantly worse in patients with AFP-L3 ≥10% than in patients with AFP-L3 <10%. Pre-treatment AFP-L3 values have also been reported to be correlated with poorly differentiated cancer and poor prognosis (40,41). HCC patients positive for AFP-L3 (AFP-L3 ≥10%) have the potential for faster growth and early metastasis (45). The elevation of pretreatment AFP-L3 levels significantly decreased the survival rate of patients who underwent RFA (21). Our results suggest that elevated AFP-L3 levels reflect faster distant recurrence of HCCs after RFA.

Then, we examined several significant risk factors for disease-free survival and found that low Alb (≤3.5 mg/dl)

and high AFP-L3 ($\geq 10\%$) were predictive factors for cumulative recurrence-free survival after RFA on univariate analysis. The risk factors for tumor recurrence-free survival after curative resection were reported to include not only tumor-related factors, such as tumor size, nodule number and tumor location, but also liver-related factors, such as platelet count, prothrombin time, serum ALT and serum Alb (1,6,46,48). The present study demonstrated that elevated tumor marker levels, especially elevated AFP-L3 levels, were also risk factors for recurrence after complete RFA. Multivariate analysis demonstrated that low Alb levels and high AFP-L3 levels were independent predictive factors for the cumulative recurrence-free survival rate.

In conclusion, tumor markers have almost the same utility for the detection of recurrent HCCs after RFA as for detection of initial HCCs. Therefore, it is strongly recommended that all three markers be measured to predict and detect HCC recurrence following RFA. Especially high AFP-L3 levels should be followed closely. In addition, other new markers will be needed to establish a more efficient strategy for screening, for early detection and for prediction of HCC recurrence.

References

1. Yamashiki N, Yoshida H, Tateishi R, *et al*: Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. *J Gastroenterol Hepatol* Dec 22: 2155-2160, 2007.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin* 55: 74-108, 2005.
3. Shiratori Y, Yoshida H and Omata M: Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. *Exp Rev Anticancer Ther* 1: 277-290, 2001.
4. Yamakado K, Nakatsuka A, Takaki H, *et al*: Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. *Radiology* 247: 260-266, 2008.
5. Rossi S, Di Stasi M, Buscarini E, *et al*: Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. *Cancer J Sci Am* 1: 73-81, 1995.
6. Fuke H, Sugimoto K, Shiraki K, *et al*: Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. *Aliment Pharmacol Ther* 27: 1253-1260, 2008.
7. Yamakado K, Nakatsuka A, Akeboshi M and Takeda K: Percutaneous radiofrequency ablation of liver neoplasms adjacent to the gastrointestinal tract after balloon catheter interposition. *J Vasc Interv Radiol* 14: 1184-1186, 2003.
8. Yamakado K, Nakatsuka A, Akeboshi M, Takaki H and Takeda K: Percutaneous radiofrequency ablation for the treatment of liver neoplasms in the caudate lobe left of the vena cava: electrode placement through the left lobe of the liver under CT-fluoroscopic guidance. *Cardiovasc Interv Radiol* 28: 638-640, 2005.
9. Tateishi R, Shiina S, Yoshida H, *et al*: Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. *Hepatology* 44: 1518-1527, 2006.
10. Vivarelli M, Guglielmi A, Ruzzenente A, *et al*: Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. *Ann Surg* 240: 102-107, 2004.
11. Hong SN, Lee SY, Choi MS, *et al*: Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. *J Clin Gastroenterol* 39: 247-252, 2005.
12. Montorsi M, Santambrogio R, Bianchi P, *et al*: Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. *J Gastrointest Surg* 9: 62-67, 2005.
13. Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. *World J Gastroenterol* 12: 1175-1181, 2006.
14. Toyoda H, Kumada T, Osaki Y, Oka H and Kudo M: Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. *Hepatol Res* 37 (Suppl. 2): S166-S171, 2007.
15. Oka H, Tamori A, Kuroki T, Kobayashi K and Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *Hepatology* 19: 61-66, 1994.
16. Taketa K, Endo Y, Sekiya C, *et al*: A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma. *Cancer Res* 53: 5419-5423, 1993.
17. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y and Asakura H: The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. *Cancer* 82: 1643-1648, 1998.
18. Hippo Y, Watanabe K, Watanabe A, *et al*: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. *Cancer Res* 64: 2418-2423, 2004.
19. Tsai JF, Jeng JE, Chuang LY, *et al*: Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. *Scand J Gastroenterol* 40: 68-75, 2005.
20. Marrero JA and Lok AS: Newer markers for hepatocellular carcinoma. *Gastroenterology* 127: S113-S119, 2004.
21. Toyoda H, Kumada T, Kaneoka Y, *et al*: Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. *J Hepatol* 49: 223-232, 2008.
22. Tsukuma H, Hiyama T, Tanaka S, *et al*: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 328: 1797-1801, 1993.
23. Taketa K, Sekiya C, Namiki N, *et al*: Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. *Gastroenterology* 99: 508-518, 1990.
24. Liebman HA, Furie BC, Tong MJ, *et al*: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. *N Engl J Med* 310: 1427-1431, 1984.
25. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R and Tomita K: Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. *Oncology* 62: S57-S63, 2002.
26. Toyoda H, Kumada T, Kiriya S, *et al*: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 4: 111-117, 2006.
27. Shiraki K and Takase K: New serological markers for hepatocellular carcinoma. *Hepatol Res* 33: 195-197, 2005.
28. Snowberger N, Chinnakotla S, Lepe RM, *et al*: Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. *Aliment Pharmacol Ther* 26: 1187-1194, 2007.
29. Daniele B, Bencivenga A, Megna AS and Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. *Gastroenterology* 127 (Suppl. 1): S108-S112, 2004.
30. Yamakado K, Nakatsuka A, Ohmori S, *et al*: Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. *J Vasc Interv Radiol* 13: 1225-1232, 2002.
31. Hasegawa S, Yamasaki N, Hiwaki T, *et al*: Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. *Cancer* 86: 1683-1690, 1999.
32. Ebara M, Okabe S, Kita K, *et al*: Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. *J Hepatol* 43: 458-464, 2005.
33. Khan KN, Yatsushashi H, Yamasaki K, *et al*: Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. *J Hepatol* 32: 268-278, 2000.
34. Horiike N, Iuchi H, Ninomiya T, *et al*: Influencing factors for recurrence of hepatocellular carcinoma treated with radiofrequency ablation. *Oncol Rep* 9: 1059-1062, 2002.
35. Izumi N, Asahina Y, Noguchi O, *et al*: Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. *Cancer* 91: 949-956, 2001.



SPANDIDOS K, Saitoh S, Koida I, *et al*: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *Hepatology* 18: 47-53, 1993.

37. Sherman M, Peltekian KM and Lee C: Screening of hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. *Hepatology* 22: 432-438, 1995.
38. Trevisani F, D'Intino PE, Morselli-Labate AM, *et al*: Serum α -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. *J Hepatol* 34: 570-575, 2001.
39. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME and Min AD: Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. *Am J Gastroenterol* 95: 1535-1538, 2000.
40. Oka H, Saito A, Ito K, *et al*: Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of *Lens culinaris* agglutinin-reactive alpha-fetoprotein. *J Gastroenterol Hepatol* 16: 1378-1383, 2001.
41. Yamashita F, Tanaka M, Satomura S and Tanikawa K: Prognostic significance of *Lens culinaris* agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. *Gastroenterology* 111: 996-1001, 1996.
42. Nakashima O and Kojiro M: Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. *J Hepatobiliary Pancreat Surg* 8: 404-409, 2001.
43. Kumada T, Nakano S, Takeda I, *et al*: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. *Hepatology* 25: 87-92, 1997.
44. Sugimoto R, Okuda K, Tanaka M, Aoyagi S and Kojiro M: Metachronous multicentric occurrence of hepatocellular carcinoma after surgical treatment - clinicopathological comparison with recurrence due to metastasis. *Oncol Rep* 6: 1303-1308, 1999.
45. Debruyne EN and Delanghe JR: Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. *Clin Chim Acta* 395: 19-26, 2008.
46. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK and Fan ST: Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. *J Gastrointest Surg* 12: 183-191, 2008.
47. Kobayashi M, Ikeda K, Kawamura Y, *et al*: High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. *Cancer* 115: 571-580, 2009.